Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Chiesi Farmaceutici S.p.A
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
A research study to evaluate the effect of a new fixed triple combination of beclometasone dipropionate + formoterol fumarate + glycopyrronium bromide at medium dose in patients with uncontrolled asthma
- To demonstrate the superiority of CHF 5993 100/6/12.5 pMDI compared to CHF 1535 100/6 pMDI in terms of change from baseline in pre-dose FEV1 at Week 26. - To demonstrate the reduction of moderate an...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
EVALUATION OF CARDIAC SAFETY, TOLERABILITY AND EFFICACY OF CUMULATIVE DOSES OF CHF5188 pMDI (FIXED COMBINATION BUDESONIDE/CARMOTEROL 200/1 µg) COMPARED TO SAME CUMULATIVE DOSES OF CARMOTEROL pMDI AND PLACEBO IN ASTHMATIC PATIENTS A MONOCENTER, RANDOMISED, DOUBLE-BLIND, 3-WAY, CROSS-OVER CLINICAL STUDY
To establish the cardiac safety (QTcB interval) and the efficacy (FEV1) of cumulative-doses of CHF 5188.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
A clinical trial to evaluate the evolution of a new medicine, CHF 6001 DPI in patients with chronic lung obstruction
To evaluate the effect of CHF 6001 on biomarkers of inflammation in induced sputum and in blood
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
Research study to evaluate the effect of different doses of inhaled glycopyrronium bromide via Nexthaler in COPD patients
The primary objective is to identify the optimal dose of CHF 5259 glycopyrronium bromide (GB) to be further developed for the treatment of patients with COPD.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
Comparison Of Envarsus® and Advagraf® In adult kidney transplant patients Comparaison de l'Envarsus® et de l'Advagraf® chez des patients adultes ayant subi une transplantation rénale
- To compare tacrolimus pharmacokinetics early after transplantation following administration of Envarsus® tablets or Advagraf® capsules in adult de-novo kidney transplant recipients
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
EVALUATION OF THE 24-HOUR TROUGH FEV1 FOLLOWING 7 DAYS OF DOSING WITH CHF4226 2µg ONCE DAILY. A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL GROUP, PLACEBO AND ACTIVE (FORMOTEROL 12µg B.I.D.) CONTROLLED STUDY FOLLOWED BY A 3-WEEK OPEN LABEL EXTENSION (TO EITHER CHF4226 2µg Q.D. OR FORMOTEROL 12µg B.I.D. IN A 2:1 RATIO) FOR THE EVALUATION OF SAFETY AND TOLERABILITY
To characterise the mean trough 23-24 hrs FEV1 following 7 days of dosing of CHF 4226 2µg given o.d. and to compare it with placebo.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
A single-dose, open-label, randomized, 2-way crossover, clinical pharmacology study of four inhalations of CHF 1535 100/6 NEXT DPI® (fixed combination of beclomethasone dipropionate 100μg plus formoterol fumarate 6 μg) versus the same dose of CHF 1535 100/6 pMDI both administered with charcoal block
To compare the lung bioavailability of B17MP (active metabolite of BDP) and formoterol after four inhalations using CHF 1535 100/6 NEXT DPI® and CHF 1535 100/6 pMDI using AeroChamber PlusTM spacer, wi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
A study to evaluate whether a new inhaled medicine (combination of beclometasone plus formoterol plus glycopyrronium) works as well as a combination of licensed medicines (combination of fluticasone plus vilanterol and tiotropium) in patient with chronic obstructive pulmonary disease
To demonstrate the non-inferiority of CHF 5993 pMDI versus fixed combination of fluticasone furoate/vilanterol plus tiotropium in terms of quality of life (change from baseline in the St. George’s Res...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
Effect of fixed combination of beclomethasone dipropionate/formoterol fumarate (BDP/FF), as reliever, upon exhaled nitric oxide in asthma. FENOMENO study (Fractional Exhaled Nitric Oxide-Multiple Expiration flow of NO). A single-centre, placebo controlled, randomized, double blind, cross-over study
To evaluate in asthmatic patients treated with CHF1535 maintenance therapy the effects of inhaled CHF1535 or salbutamol as reliever medications on airway inflammation as reflected by fractional exhale...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
A study, conducted in several sites, with a duration of 2 years to evaluate the Safety and Efficacy of a new drug named velmanase alfa used in children with Alpha-Mannosidosis below 6 years of age
The main objectives of this trial are to evaluate safety and efficacy of repeated velmanase alfa i.v. infusions in pediatric alpha-mannosidosis patients aged less than 6 years" as per section 2 of the...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
Suivant